Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGLN1 | Q9GZT9 | 19/20 | 0.76 |
| ▸ | EGLN3 | Q9H6Z9 | 6/20 | 0.76 |
| ▸ | FLT1 | P17948 | 5/20 | 0.76 |
| ▸ | VEGFA | P15692 | 5/20 | 0.76 |
| ▸ | FTO | Q9C0B1 | 2/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1923034 | 0.86 | EGLN1 (1.00) | EGLN1EGLN3FLT1VEGFAFTO | |
| SCHEMBL1921635 | 0.84 | EGLN1 (0.77) | EGLN1EGLN3FLT1VEGFAFTO | |
| SCHEMBL1921647 | 0.84 | EGLN1 (1.00) | EGLN1EGLN3FLT1VEGFA | |
| SCHEMBL14308516 | 0.84 | EGLN1 (0.81) | EGLN1EGLN3FLT1VEGFAFTO | |
| SCHEMBL19676954 | 0.81 | EGLN1 (0.77) | EGLN1EGLN3FLT1VEGFAFTO | |
| SCHEMBL1920661 | 0.79 | EGLN1 (0.77) | EGLN1EGLN3FLT1VEGFAFTO | |
| SCHEMBL24405090 | 0.78 | EGLN1 (0.58) | EGLN1EGLN3FLT1VEGFAFTO | |
| SCHEMBL5637785 | 0.77 | EGLN1 (0.66) | EGLN1EGLN3FLT1VEGFA | |
| SCHEMBL20171231 | 0.76 | EGLN1 (0.72) | EGLN1EGLN3FLT1VEGFAFTO | |
| SCHEMBL14331202 | 0.75 | EGLN1 (0.71) | EGLN1EGLN3FLT1VEGFA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3357911-A1 | PROLYL HYDROXYLASE INHIBITORS AND METHODS OF USE | Akebia Therapeutics Inc. (US) | 2018-08-08 | — | — | EP | disclosed |
| EP-3323807-A1 | PROLYL HYDROXYLASE INHIBITORS AND METHODS OF USE | Akebia Therapeutics, Inc. (US) | 2018-05-23 | — | — | EP | disclosed |